Calvisken
Calvisken Brand names, Calvisken Analogs
Calvisken Brand Names Mixture
- Viskazide 10/25tab (Hydrochlorothiazide + Pindolol)
- Viskazide 10/50tab (Hydrochlorothiazide + Pindolol)
Calvisken Chemical_Formula
C14H20N2O2
Calvisken RX_link
http://www.rxlist.com/cgi/generic3/pindolol.htm
Calvisken fda sheet
Calvisken msds (material safety sheet)
Calvisken Synthesis Reference
No information avaliable
Calvisken Molecular Weight
248.321 g/mol
Calvisken Melting Point
167-171 oC
Calvisken H2O Solubility
7880 mg/L
Calvisken State
Solid
Calvisken LogP
2.525
Calvisken Dosage Forms
Tablet
Calvisken Indication
For the management of hypertension, edema, ventricular tachycardias, and atrial fibrillation.
Calvisken Pharmacology
Pindolol is a non-selective beta-adrenergic antagonist (beta-blocker) which possesses intrinsic sympathomimetic activity (ISA) in therapeutic dosage ranges but does not possess quinidine-like membrane stabilizing activity. Pindolol impairs AV node conduction and decreases sinus rate and may also increase plasma triglycerides and decrease HDL-cholesterol levels. Pindolol is nonpolar and hydrophobic, with low to moderate lipid solubility. Pindolol has little to no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, pindolol has little direct myocardial depressant activity and does not have an anesthetic-like membrane-stabilizing action.
Calvisken Absorption
Rapidly and reproducibly absorbed (bioavailability greater than 95%).
Calvisken side effects and Toxicity
LD50=263 mg/kg (orally in rats). Signs of overdose include excessive bradycardia, cardiac failure, hypotension, and bronchospasm.
Calvisken Patient Information
Calvisken Organisms Affected
Humans and other mammals
